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Letter to the editor: The need for a new classification of cholesterol lowering therapies  
 
Re: Cicero AFG, Morbini M, Bove M, et al. Additional therapy for cholesterol lowering in 
ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit 
of a university lipid clinic. Curr Med Res Opin 2016. doi: 10.1080/03007995.2016.1190326 
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Dear Editor: 
Lipid lowering therapy (LLT) with statins have the strongest evidence regarding the 
reduction in cardiovascular (CV) events and total mortality and thus are the cornerstone of 
every global guideline after lifestyle. Despite this evidence there is a gap between current 
treatment uptake and clinical guidelines including a failure to achieve cholesterol targets in 
patients. We think that there are 3 main factors contributing in this difference. The first is the 
relative effectiveness of the available LLT, and statin intolerance and the use of alternative 
drugs to statins (1). The second are patient related factors and recently, considerable 
emphasis has been placed on improving patient compliance, in light of the extremely 
disappointing persistence to statin therapy. The third important factor which needs 
considerable attention is the view of health care professionals towards LLT and whether 
uncertainties in particular about the use of more potent statin regimes still persist and thus 
limit effective utilisation of LLT.                                 
The Hungarian MULTI GAP study performed yearly between 2004 and 2013 on patients 
with known vascular disease has demonstrated a continuous decrease in LDL-cholesterol 
(LDL-C) level achievement over time. In the past couple of years the achieved average LDL-
C level in high-risk patients was near the 2.5 mmol/l goal, but a further decrease of 0.7 
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mmol/l would be required to reach the 1.8 mmol/l target level for very high risk patients. 
Among the statins used rosuvastatin and atorvastatin dominate and these potent statins are 
being used with increasing frequency (2,3). 
More recently the annual decline in achieved LDL-C levels has plateaued. The background is 
unclear but includes factors such as: the reluctance of doctors to increase the statin dose; 
reluctance to switch to more potent statins; reluctance to initiate combination therapy when 
their patients do not reach target levels; or a lack of awareness of the benefits of further 
reductions in LDL-C in high risk groups.  
The CEPHEUS study (Centralized Pan-European survey on the under-treatment of 
hypercholesterolaemia) has shown that failure to achieve lipid goals do not trigger further 
modification of LLT (4). Doubling the statin dose or changing to a more potent statin are 
potential options when lipid goals are not reached but the gain may be modest. For instance 
doubling the dose of current statin, results in a further 6% LDL-C decrease (rule of six) (5). 
In the Hungarian MULTI GAP study the plateau in the LDL-C decrease was observed 
despite the more frequent use of the most potent statins. In a retrospective database analysis 
using atorvastatin monotherapy less than half of patients achieved their goals (6). In a study 
based on rosuvastatin administration, in clinical trials rather than real world data, the 2.5 
mmol/l LDL-C goal attainment was under 60%, and less than 20% of patients achieved the 
very high risk goal of 1.8 mmoL/l (7). In EUROASPIRE IV the LDL-C goal of 2.5 mmol/l 
was achieved by half of the patients, the 1.8 mmol/l by less than 30% (8).  
The results of IMPROVE-IT support the “lower the better” concept and have proven that a 
non-statin drug which lowers LDL-C is able for significantly reducing the number of vascular 
events (9). These results provide us with evidence based data for the statin-ezetimibe 
combination.  
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Achieving lipid goals at the first attempt  
In order to improve compliance, the continuous education of patients is important. Also 
continuous emphasis on improving the doctors’ knowledge about LLTs as data emerges is 
essential. Even with further education intensification of statin therapy may not offer much 
more incremental reduction in LDL-C thus ESC/EAS targets may not be attained as doubling 
statin dose only results in a further 6% reduction in LDL-C. 
 The ‘old fashioned’ LLT starts with a low dose statin and is based on titration of the dose. 
Since the titration often is omitted, in this type of approach initiating LLT without uptitration 
is believed to be one of the obvious causes of failing to achieve the target levels. Contrary to 
this traditional approach the ESC/EAS guidelines recommend defining the desired percentage 
LDL-C lowering required to achieve LDL-C goals and to start an appropriate therapy in one 
step (10). This could be a useful approach but requires that the physician calculate the 
expected percentage reduction and the best approach at the outset. This is ideal for statin 
naïve patients and the guidelines do not give a clear recommendation for cases already 
receiving LLT. 
The combination of ezetimibe could be useful, to help target goal attainment and thus result 
in reduction of risk. Masana et al have tried to simplify the ESC/EAS guidelines by providing 
scenarios when statins suffice or when combination therapy is desirable based on baseline 
LDL-C and baseline risk (11). This approach could be ideal in statin naive patients where the 
desired and expected effect is predictable. The drawback of this approach, again, the lack a 
consideration of former LLT in patients already receiving statins.  
We propose an algorithm to guide physicians when faced with patients not at goal who statin 
naïve or are already receiving LLT.  
Table 1A presents a classification of the commonly used LLTs. Based on the expected LDL-
C lowering effect the therapies are divided in 4 groups. The bile acid absorption inhibitors 
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(resins), since it is not commonly used in the everyday LLT, are mentioned only as an option 
for very high intensity lipid lowering combinations as an option for patients with high 
starting LDL-C levels. Here we have included the fenofibrate which is primarily used in 
combination with statins in cases with high triglyceride and/or low HDL-cholesterol for the 
reduction of residual lipid risk, but its 10% LDL-C reduction is modest in effect but these 
mediacations are relatively inexpensive in contrast to more potent but expensive Proprotein 
convertase subtilisin-like kexin type 9 inhibitors (PCSK9i). The administration of 
nutraceuticals is acceptable in any level of risk to “help” statins’ LDL-C lowering effect, and 
could be considered as inexpensive though less potent options before PCSK9i-s. The 
fenofibrate and nutraceuticals should be considered mainly in younger patients with very 
high LDL-C levels and in primary prevention cases.  This table can be used to classify the 
current therapy of patients already on LLT and for choosing the appropriate therapy after the 
determination of the desired level for change.  
- First we have to define the patient’s LDL-C goal and the percent needed to reach it 
- If the patient is on LLT, 
o using table 1.A classify the intensity of the treatment 
o based on the risk category using table I.B or C determine the intensity of 
therapy needed to reach the goal 
o using table 1.A choose the appropriate option 
- for LLT naïve patients 
o based on the risk category using table 1.B or C determine the intensity of 
therapy needed to reach the goal 
o using table 1.A choose the appropriate option 
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Using recommendation for a one step therapy will obviously not entirely solve the problems 
of achieving optimal LLT, but at least guide doctors regarding the appropriate treatment 
option for better LDL-C goal attainment in high and very high risk patients. The 
recommendation of LLTs except PCSK9i-s is for the present day practice; the use of 
PCSK9i-s is a very promising but expensive option currently mainly for cases with very high 
LDL-C, familial hypercholesterolaemia and statin intolerant very high risk patients. 
 
Sincerely, 
Laszlo Mark
a
 , György Paragh
b
 , Kausik K. Ray
c
 
 
a
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b
 Medical and Health Science Centre, University of Debrecen, 1st Department of Medicine, 
Debrecen, Hungary 
 
c
 Department of Primary Care and Public Health, School of Public Health, Imperial College 
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Table 1.  
A. Classification of the commonly used cholesterol lowering 
therapies (after Masana) 
 
LICLT (Low intensity cholesterol lowering therapy) LDL-C lowering  30% 
Simvastatin10 mg 
Pravastatin 10-20 mg 
Pitavastatin 1 mg 
Ezetimibe 
 
MICLT (Mild intensity cholesterol lowering therapy) LDL-C lowering 30-49% 
Atorvastatin 10-20 mg  
Rosuvastatin 5-10 mg 
Simvastatin 20-40 mg  
Fluvastatin XL 80 mg 
Pitavastatin 2-4 mg 
Simvastatin 10 mg + ezetimibe  
Pravastatin 20 mg + ezetimibe 
Pitavastatin 1 mg + ezetimibe 
 
HICLT (High intensity cholesterol lowering therapy) LDL-C lowering 50-60% 
Atorvastatin 40-80 mg  
Rosuvastatin 20-40 mg 
Simvastatin 20-40 mg + ezetimibe 
Fluvastatin XL 80 mg + ezetimibe 
Pitavastatin 2-4 mg + ezetimibe 
Pravastatin 40 mg + ezetimibe 
Atorvastatin 10-20 mg + ezetimibe 
Rosuvastatin 5-10 mg + ezetimibe 
 
 
VHICLT (Very high intensity cholesterol lowering therapy) LDL-C lowering  60% 
Atorvastatin 40-80 mg + ezetimibe 
Rosuvastatin 20-40 mg+ ezetimibe 
Any HICLT + bile acid absorption inhibitor 
Any HICLT or VHICT + fenofibrate and/or nutraceuticals 
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 B. Recommendation for lipid lowering therapy in very high risk 
patients to achieve the 1.8 LDL-cholesterol goal 
 
 
   Recommended LDL-C lowering group for patients 
 
Starting  statin naive on low intensity on middle  on high 
LDL-C level    cholesterol   intensity cholesterol intensity       
lowering therapy  lowering therapy cholesterol  
lowering th 
 
1.80-2.49  MICLT  HICLT   VHICLT   VHICLT 
 
2.50-3.59  HICLT  VHICLT   VHICLT+   VHICLT+
        PCSK9i   PCSK9i 
 
3.59-4.99  VHICLT  VHICLT+   VHICLT+   VHICLT+ 
     PCSK9i   PCSK9i   PCSK9i 
 
5.00-   VHICLT+  VHICLT+  VHICLT+   VHICLT+ 
   PCSK9i  PCSK9i   PCSK9i   PCSK9i 
 
 
 
C. Recommendation for lipid lowering therapy in very high risk 
patients to achieve the 2.5 LDL-cholesterol goal 
 
   Recommended LDL-C lowering group for patients 
 
Starting  statin naive on low intensity on middle  on high 
LDL-C level    cholesterol   intensity cholesterol intensity       
lowering therapy  lowering therapy cholesterol  
lowering th 
 
2.50-3.55  LICLT  MICLT   HICLT   VHICLT 
 
3.60-4.99  MICLT  HICLT   VHICLT   VHICLT+ 
           PCSK9i 
5.00-5.99  HICLT  VHICLT   VHICLT+ 
        PCSK9i 
6.0   VHICLT  VHICLT+ 
     PCSK9i 
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